Merck KGaA, Darmstadt, Germany, statement on Rebif (interferon beta-1a) donation to INSERM

As Merck KGaA, Darmstadt, Germany is a company that is dedicated to human progress and to making a lasting difference on patients’ lives, we are fully committed to contributing to solutions related to global...

19 Mar 2020 | Darmstadt, Germany

COMPANY STATEMENT

As Merck KGaA, Darmstadt, Germany is a company that is dedicated to human progress and to making a lasting difference on patients’ lives, we are fully committed to contributing to solutions related to global health crises such as COVID-19.

As part of the global effort to investigate potential therapeutics for COVID-19 and our support of independent research, Merck KGaA, Darmstadt, Germany recently donated a supply of interferon beta-1a (Rebif®) to the French Institut National de la Santé et de la Recherche Médicale (INSERM) following a request for use in a clinical trial. The trial is sponsored by INSERM and its launch has been announced by the French Health authorities on March 11th. To date, Merck KGaA, Darmstadt, Germany’s interferon beta-1a is not approved by any regulatory authority for the treatment of COVID-19 or for use as an antiviral agent.

We continue to work closely with global health authorities to respond to the needs of patients impacted by COVID-19.

Downloads

Related News

View All News
  1. Press Releases

    MilliporeSigma Announces Opening of New € 29 Million Biologics Testing Center ...

    MilliporeSigma today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.

    2022/09/21